FDA clears first at-home brain device for depression

FDA approves first brain stimulation device for home depression treatment. Flow Neuroscience's FL-100 headset uses electrical ...
Bodybuilding Bros on MSN

How regular exercise affects depression according to Cochrane Review

The research published in the Cochrane Library, Neuroscience & Biobehavioral Reviews revealed that when it comes to ...

Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting

Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) on Day ...
New Atlas

First US at-home depression kit on its way after trial shows relief in weeks

In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved the first at-home brain-stimulation device to treat moderate to severe major ...
Morningstar

Matter Neuroscience announces collaboration with Stanford Medicine combining Matter protocol with real-time fMRI neurofeedback to support emotion-based interventions in depression

This collaboration sets out to explore whether using the Matter Neuroscience protocol combined with real-time neurofeedback can influence emotional brain networks relevant to depression. PALO ALTO, ...

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2026 Milestones

Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate ...
Pharmabiz

Alto Neuroscience receives US patent for ALTO-207; strengthens IP portfolio for patients with treatment-resistant depression

Alto Neuroscience receives US patent for ALTO-207; strengthens IP portfolio for patients with treatment-resistant depression: Mountain View, California Saturday, January 17, 2026, ...
MarketWatch

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

The MarketWatch News Department was not involved in the creation of this content. -- Successful outcome from recent FDA meeting guides Alto's plan to accelerate development of ALTO-207, with capital ...
Seeking Alpha

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash ...

– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – ...
Benzinga.com

Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
Psychology Today

Depression and the Heart

Depression is not only a disorder of mood but also a condition that affects the heart and blood vessels, and can carry ...
Morningstar

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting – Successful outcome from recent FDA ...